相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env
Amelia Escolano et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy
Devi SenGupta et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
Pathways towards human immunodeficiency virus elimination
Prasanta K. Dash et al.
EBIOMEDICINE (2020)
Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption
Donn J. Colby et al.
NATURE MEDICINE (2020)
Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques
Galit Alter et al.
CELL (2020)
Reanalysis of Gene Expression Profiles of CD4+T Cells Treated with HIV-1 Latency Reversal Agents
Antonio Victor Campos Coelho et al.
MICROORGANISMS (2020)
Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques
Amelia Escolano et al.
NATURE (2019)
The Landscape of Persistent Viral Genomes in ART-Treated SIV, SHIV, and HIV-2 Infections
Alexandra M. Bender et al.
CELL HOST & MICROBE (2019)
TLR7 agonist administration to SIV-infected macaques receiving early initiated cART does not induce plasma viremia
Gregory Q. Del Prete et al.
JCI INSIGHT (2019)
Getting the Kill into Shock and Kill: Strategies to Eliminate Latent HIV
Youry Kim et al.
CELL HOST & MICROBE (2018)
Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)
Dan H. Barouch et al.
LANCET (2018)
TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy
So-Yon Lim et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
The human naive B cell repertoire contains distinct subclasses for a germline-targeting HIV-1 vaccine immunogen
Colin Havenar-Daughton et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Therapeutic vaccination for HIV: hopes and challenges
Kathryn E. Stephenson
CURRENT OPINION IN HIV AND AIDS (2018)
Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys
Erica N. Borducchi et al.
NATURE (2018)
Eradication of HIV-1 latent reservoirs through therapeutic vaccination
Joshua Pankrac et al.
AIDS RESEARCH AND THERAPY (2017)
Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo
Joshua A. Horwitz et al.
CELL (2017)
HIV reservoirs: what, where and how to target them
Melissa J. Churchill et al.
NATURE REVIEWS MICROBIOLOGY (2016)
Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice
Amelia Escolano et al.
CELL (2016)
HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies
Jon M. Steichen et al.
IMMUNITY (2016)
The Latent Reservoir for HIV-1: How Immunologic Memory and Clonal Expansion Contribute to HIV-1 Persistence
Alexandra J. Murray et al.
JOURNAL OF IMMUNOLOGY (2016)
Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys
Erica N. Borducchi et al.
NATURE (2016)
HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogene
Joseph G. Jardine et al.
SCIENCE (2016)
Reversal of Latency as Part of a Cure for HIV-1
Thomas Aagaard Rasmussen et al.
TRENDS IN MICROBIOLOGY (2016)
A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes
R. Brad Jones et al.
PLOS PATHOGENS (2016)
Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys
Dan H. Barouch et al.
SCIENCE (2015)
Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques
Sampa Santra et al.
PLOS PATHOGENS (2015)
Emerging strategies to deplete the HIV reservoir
Nancie M. Archin et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2014)
New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo
C. Korin Bullen et al.
NATURE MEDICINE (2014)
Pharmacokinetic and Pharmacodynamic Properties of GS-9620, a Novel Toll-Like Receptor 7 Agonist, Demonstrate Interferon-Stimulated Gene Induction without Detectable Serum Interferon at Low Oral Doses
Abigail Fosdick et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist
Uri Lopatin et al.
ANTIVIRAL THERAPY (2013)
Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors
Joseph Jardine et al.
SCIENCE (2013)
Type I Interferon Upregulates Bak and Contributes to T Cell Loss during Human Immunodeficiency Virus (HIV) Infection
Joseph A. Fraietta et al.
PLOS PATHOGENS (2013)
Toll-like receptors in innate immunity
K Takeda et al.
INTERNATIONAL IMMUNOLOGY (2005)
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
F Heil et al.
SCIENCE (2004)
分享论文
